HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the...
Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
Seaking AlphaSeeking Alpha / Seaking Alpha 6 hours ago 1 Views
Comments